Log in or Sign up for Free to view tailored content for your specialty!
Hepatitis C News
Universal screening for HCV superior to risk-based approach in pregnant women
SAN FRANCISCO — Universal screening of pregnant women at risk for hepatitis C was more efficient and cost-effective compared with risk-based screening, according to data presented at The Liver Meeting 2018.
Mavyret SVR high in patients with Sovaldi, NS5A inhibitor experience
SAN FRANCISCO — Mavyret was highly effective and well-tolerated in patients with chronic hepatitis C genotype 1 who had experience with a combination of Sovaldi, NS5A inhibitor and ribavirin, according to data presented at The Liver Meeting 2018.
Log in or Sign up for Free to view tailored content for your specialty!
Healio to report live from The Liver Meeting 2018
SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.
AbbVie launces HCV resource website with national patient data
AbbVie announced a new interactive online resource, MappingHepC.com, that features national and state-level data on hepatitis C screening, diagnosis and treatment, according to a press release.
WHO guidelines address need for physical health management in severe mental illness
WHO has released evidence-based guidelines for managing physical health conditions in adults with severe mental disorders, according to a press release.
HCC recurrence rates do not differ after interferon vs. DAA therapy
Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.
Unrestricted DAA access improves HCV treatment uptake among PWIDs
Data from Australia’s annual bio-behavioral surveillance of people who inject drugs attending needle syringe programs between 2015 and 2017 showed a significant increase in hepatitis C treatment uptake and decrease in viremic prevalence, especially among older patients and those with a history of opioid substitution therapy.
6 reports on improving HCV control through investment, screening
Both in the U.S. and internationally, researchers continue to invest time and money toward the eradication of hepatitis C through clinical programs, awareness campaigns, and ongoing efficacy studies.
Daklinza-Sovaldi produces similar SVR as Epclusa for HCV genotypes 2, 3
Daklinza with Sovaldi and ribavirin produced similar rates of sustained virologic response among patients with hepatitis C genotypes 2 and 3 as those treated with Epclusa, according to a recently published study.
HCV eradication program achieves 97% cure among patients on dialysis
Fresenius Kidney Care developed a hepatitis C eradication program that resulted in a 97% cure rate among patients on dialysis who received direct-acting antiviral therapy.